DAVID N GILL
CIK 1106519 · President and CFO · last filed 2026-02-19
DAVID N GILL is a President and CFO who has filed 63 SEC Form 4 insider transactions across 9 companies since 2007. The most recent filing, for EOLS, was dated Feb 19, 2026. Across all open-market trades the lifetime net is −$459.9K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.1M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$1.15M
9
63
-$459.9K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| EOLS | Director | 86,887 | $6.73 | $584.7K | -$203.1K | 13 | 2026-02-19 |
| Y-mAbs Therapeutics, Inc. (YMAB) Delisted | Director | 30,905 | $8.61 | $266.1K | -$364.6K | 10 | 2025-07-02 |
| Strongbridge Biopharma plc (SBBP) Delisted | Director | 0 | $2.00 | $0 | $17.0K | 8 | 2021-10-06 |
| SSKN | Director | 64,694 | $0.15 | $9.7K | $0 | 3 | 2019-11-26 |
| MELINTA THERAPEUTICS, INC. /NEW/ (MLNT) Delisted | Director | 6,000 | — | — | $30.4K | 3 | 2019-06-12 |
| MELINTA THERAPEUTICS, INC. /NEW/ (CEMP) Delisted | Director | 5,000 | — | — | $14.7K | 7 | 2017-01-05 |
| EndoChoice Holdings, Inc. (GI) Delisted | President and CFO | 0 | — | — | $33.2K | 5 | 2016-11-23 |
| ISOTIS INC (ISOT) Delisted | Director | — | — | — | $0 | 1 | 2007-10-30 |
| LMAT | Director | 6,005 | $91.96 | $552.2K | $12.3K | 3 | 2007-07-20 |
Recent Filings
63 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-02-19 | EOLS | Grant (A) | +45,559 | $0 | EDGAR |
| 2025-09-18 | — | Disp (D) | −30,905 | -$50.1K | |
| 2025-07-02 | Y-mAbs Therapeutics, Inc. (YMAB) Delisted | Grant (A) | +25,080 | $0 | EDGAR |
| 2025-03-11 | EOLS | Grant (A) | +7,364 | $0 | EDGAR |
| 2024-06-13 | Y-mAbs Therapeutics, Inc. (YMAB) Delisted | Grant (A) | +3,495 | $0 | EDGAR |
| 2024-05-15 | EOLS | Sell (S) | −10,361 | -$131.0K | EDGAR |
| 2024-02-09 | EOLS | Grant (A) | +6,464 | $0 | EDGAR |
| 2023-06-09 | Y-mAbs Therapeutics, Inc. (YMAB) Delisted | Grant (A) | +2,330 | $0 | EDGAR |
| 2023-01-31 | EOLS | Grant (A) | +8,293 | $0 | EDGAR |
| 2022-07-19 | Y-mAbs Therapeutics, Inc. (YMAB) Delisted | Grant (A) | — | $0 | EDGAR |